Program
ceftobiprole medocaril
Also written as “Ceftobiprole medocaril”, “Ceftobiprole medocaril sodium” and “Ceftobiprole Medocaril”.
Its studies are mostly in Community-Acquired Pneumonia · Staphylococcal Skin Infections · Endocarditis, Bacterial · Staphylococcal Infections · Neonatal Sepsis, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Basilea Pharmaceutica | 100 open or running | phase 3since Sep 13, 2005 | Sep 13, 2005 | none ahead |
| ISTx | 11 open or running | phase 3since Oct 19, 2026 | Oct 19, 2026 | Oct 31, 2028phase 3 · NCT07929493 |
Also a collaborator on its studies: Innoviva Specialty Therapeutics.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 13, 2005First studies: 2 phase 3 studies in Skin Diseases, InfectiousNew to Basilea PharmaceuticaBasilea Pharmaceutica · NCT00210899, NCT00228982
- May 12, 2006Phase 3 study in PneumoniaBasilea Pharmaceutica · NCT00326287 · 638 enrolled
- Jul 19, 2007Phase 2 study in BacteremiaBasilea Pharmaceutica · NCT00505258
- Sep 11, 2007Phase 3 study in FeverBasilea Pharmaceutica · NCT00529282 · 2 enrolled
- Aug 5, 2015Phase 1 study in Bacterial InfectionsBasilea Pharmaceutica · NCT02527681 · 15 enrolled · United States, Belgium, Germany and more
- Apr 27, 20172 phase 3 studiesBasilea Pharmaceutica · NCT03138733, NCT03137173
- Jan 30, 2018Phase 3 study in Community-Acquired PneumoniaBasilea Pharmaceutica · NCT03439124 · 138 enrolled · Bulgaria, Georgia, Hungary and more
- Apr 17, 2023Phase 3 study in Neonatal SepsisBasilea Pharmaceutica · NCT05856227 · 9 enrolled · United States, Bulgaria, Estonia and more
- Oct 19, 2026ISTx’s first study: phase 3 study in Endocarditis, BacterialNew to ISTxISTx · NCT07929493 · 60 planned
Ahead
- Oct 31, 2028Primary completion: phase 3 study in Endocarditis, BacterialISTx · NCT07929493
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Penicillin-binding protein 1 inhibitor; Penicillin-binding protein 2 inhibitor; Penicillin-binding protein inhibitor; Penicillin-binding protein 4 inhibitor”ChEMBL 37, by rule
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07929493Endocarditis, Bacterial | 3 | Not yet recruiting | ISTx | Oct 31, 2028 | 60 |
| NCT05856227Neonatal Sepsis · United States, Bulgaria, Estonia and more | 3 | Completed | Basilea Pharmaceutica | Dec 18, 2024 | 9 |
| NCT03439124Community-Acquired Pneumonia · Bulgaria, Georgia, Hungary and more | 3 | Completed | Basilea Pharmaceutica | Mar 16, 2020 | 138 |
| NCT03138733Staphylococcal Infections · United States, Argentina, Bulgaria and more | 3 | Completed | Basilea Pharmaceutica | Mar 11, 2022 | 390 |
| NCT03137173Acute Bacterial Skin and Skin Structure Infections · United States, Bulgaria, Hungary and more | 3 | Completed | Basilea Pharmaceutica | Apr 22, 2019 | 679 |
| NCT02527681Bacterial Infections · United States, Belgium, Germany and more | 1 | Terminated | Basilea Pharmaceutica | Feb 25, 2020 | 15 |
| NCT00529282Fever | 3 | Terminated | Basilea Pharmaceutica | Jan 2008 | 2 |
| NCT00505258Bacteremia | 2 | Withdrawn | Basilea Pharmaceutica | 0 | |
| NCT00326287Pneumonia | 3 | Completed | Basilea Pharmaceutica | Jul 2007 | 638 |
| NCT00228982Skin Diseases, Infectious | 3 | Completed | Basilea Pharmaceutica | Dec 2005 | 784 |
| NCT00210899Skin Diseases, Infectious | 3 | Completed | Basilea Pharmaceutica | Oct 2006 | 828 |
How it is read
Names in the registry
- “Ceftobiprole medocaril”, 5 entries
- “ceftobiprole medocaril”, 4 entries
- “Ceftobiprole medocaril sodium”, 1 entry
- “Ceftobiprole Medocaril”, 1 entry
Conditions, from the studies’ own filings
- Community-Acquired Pneumonia, 2 studies
- Staphylococcal Skin Infections, 2 studies
- Endocarditis, Bacterial, 1 study
- Staphylococcal Infections, 1 study
- Neonatal Sepsis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.